CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO. Centogene N.V. today announced the appointment of Miguel Coego Rios as…

Read more

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

Centogene N.V. today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which…

Read more

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of…

Read more

CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases

Read more

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

Newly established WGS recommendations published in the European Journal of Human Genetics

Read more

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites…

Read more

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

Read more

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Read more

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Read more

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads